Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye
Status:
Active, not recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the combination of entinostat and pembrolizumab can be
an effective treatment for patients with melanoma of the eye (uveal melanoma) that has spread
to other sites of the body (metastatic disease). Pembrolizumab is an antibody that helps the
immune system to attack cancer cells. Although pembrolizumab has proven clinical efficacy in
treating patients with metastatic cutaneous melanoma, an effect on metastatic uveal melanoma
has not been established. Entinostat is a histone deacetylase (HDAC) inhibitor that has
effects on both cancer cells and immune regulatory cells, thus potentially enhancing the
effects of immunotherapy.